Register here for our mailing list
Epigenetics drug discovery: success delivered by BioFocus.
Shifting the ligand binding paradigm with Tag-Lite®.
Hit expansion approaches using combinations of bioisosteric transformations, similarity searches and generalized substructure searches.
p38 alpha: a fragment-based drug discovery case study at BioFocus.
Discover novel chemotypes for epigenetics tagets.
Using cell based assays to study chemokine and chemerin signalling and the development of novel anti-inflammatory drugs
Validation of a new ACTOne™ - FLIPRTETRA ® assay for measurement of peptide activity in plasma samples
Improving physiological relevance in early phase drug discovery: A focus on 7TM receptors
Screening of a Chemokine Receptor – a LigandBiased approach
Fucctional assessment of endogenous NK1 receptors using the CellKey™
A label-free Perspective on GPCR Drug Discovery. Novel Applications and Cutting Edge Technologies for GPCR Screening and Profiling
New tools offered or developed for a better understanding of the complexity of 7TM pharmacology
Some Unusual Pharmacology Seen in a beta-arrestin Assay with the Cannabinoid CB2 receptor
Discovery of GPCR ligands for GPR3, a GPCR modulating amyloid secretion in Alzheimer’s Disease
The Advantages of Fluorescence in the Study of GPCRs
Bookmark with:
BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.